Adicet reports first quarter 2021 financial results and provides business updates

Menlo park, calif. and boston, may 17, 2021 (globe newswire) -- adicet bio, inc. (nasdaq: acet), a biotechnology company discovering and developing first-in-class allogeneic gamma delta t cell therapies for cancer and other diseases, today reported financial results for the first quarter ended march 31, 2021.

ACET Ratings Summary

ACET Quant Ranking